lated, using different replication strategies that divide them into separate taxonomic families.
Unlike many viral infections where recovery is associated with immunity and life-long protection, a proportion of those infected with HBV or HCV develop chronic infection in which the virus continues to replicate in the liver. This chronic carriage of HBV or HCV can lead to progressive liver disease, which after many years can result in cirrhosis and liver cancer. Around 25% of people infected with HCV will clear the virus spontaneously but the remainder develops chronic infection. For HBV, the age at which the infection is acquired is the major factor that determines clearance or chronicity. Chronic infection is the predominant outcome if infected early in life (>90%), whereas healthy adults are unlikely to become chronically infected (<5%). In many developing countries, HBV is trans- implementation of the strategies outlined in many of these documents will be of great benefit to public health and help us redress the damage caused by this insidious virus.
